Skip to main content
. 2016 Oct 3;11(10):e0164053. doi: 10.1371/journal.pone.0164053

Fig 4. Quantitative binding of Drug Substances and Drug Product to mAb 4G2.

Fig 4

Panel A: PfAMA1 DiCo1 Drug Substance (black dotted line) and DiCo1 Drug Substance incubated with a 2.5 fold excess of 4G2 (black solid line). Panel B: PfAMA1 DiCo2 Drug Substance (blue dotted line) and DiCo2 Drug Substance incubated with a 1.5 fold excess of 4G2 (blue solid line). Panel C: PfAMA1 DiCo3 Drug Substance (red dotted line) and DiCo3 Drug Substance incubated with a 1.5 fold excess of 4G2 (red solid line). Panel D. PfAMA1 DiCo1:DiCo2:DiCo3 Drug Substance mixture (1:1:1 w/w/w) (green dotted line) incubated with a 1.5 fold excess of 4G2 (green solid line). PfAMA1 DiCos and mAb 4G2 were mixed and incubated for 1 h at room temperature before injection.